# Doxycycline, Temozolomide and Ipilimumab in Melanoma

> **NCT01590082** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Doxycycline
- **DRUG:** Ipilimumab
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01590082
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Accrual slow due to alternate trials and treatment options.
- **Last updated:** 2020-09-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590082, "Doxycycline, Temozolomide and Ipilimumab in Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01590082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*